Overview of adverse reactions during ibrutinib treatment

Ibrutinib (IMBRUVICA), as a cutting-edge treatment, has shown remarkable results in the treatment of B-cell malignancies (such as CLL/SLL and WM). However, like all drugs, ibrutinib has a range of possible adverse effects. The following is a comprehensive overview of adverse reactions that patients may experience during treatment with ibrutinib.

1. Bleeding issues: During treatment with ibrutinib, the risk of bleeding may increase, especially when used concurrently with blood thinners. Bleeding may manifest as blood in the stool, blood in the urine, vomiting bloody material, coughing up blood, skin bruising and other symptoms. Patients should watch for these signs closely and inform their doctor immediately.

2. Risk of infection: Ibrutinib may weaken the function of the immune system, thereby increasing the risk of infection. Patients should pay attention to monitoring infection symptoms such as fever, chills, weakness, etc., and seek medical treatment promptly.

3. Heart problems: Severe arrhythmias, heart failure and other heart problems have been reported in patients taking ibrutinib. Patients should pay attention to symptoms related to heart problems such as abnormal heartbeats, difficulty breathing, and dizziness.

4. Hypertension: During ibrutinib treatment, patients may develop new or worsening hypertension. The doctor will monitor the patient's blood pressure and may prescribe blood pressure medication.

5. Reduced blood cell count: Reduced blood cell count, including white blood cells, platelets, and red blood cells, is a common side effect of ibrutinib. Patients should have regular blood tests to monitor blood cell counts.

6. Second primary cancer: During the use of ibrutinib, patients may develop new cancers, such as skin cancer or cancer of other organs. Therefore, it is important to have regular skin exams and other necessary cancer screenings.

7. Tumor lysis syndrome (TLS): TLS is a serious complication caused by the rapid breakdown of cancer cells, which may lead to kidney failure, abnormal heart rhythms and epileptic seizures. Doctors will monitor patients closely to prevent the occurrence of TLS.

In addition to the serious adverse reactions mentioned above, ibrutinib may also cause a series of more common side effects, such as muscle, bone and joint pain, diarrhea, nausea, fatigue, etc. These side effects are generally mild, but patients still need to pay attention and inform their doctor promptly.

In summary, understanding the adverse effects of ibrutinib and taking appropriate preventive measures are critical to ensuring that treatment is safe and effective. Patients should pay close attention to their body's reactions and follow their doctor's recommendations for treatment and management. It is reported that the innovative drug ibrutinib has been launched in my country and has been included in medical insurance. For specific information, patients should directly consult their local medical insurance department. For patients looking for more affordable treatment options, they may consider using generic versions of ibrutinib, which are already available in Bangladesh, Laos and other countries at relatively affordable prices.